
    
      Following Desmopressin/Docetaxel treatment subjects will be subjected to routine medical
      oncology follow-up, including clinical appointments, laboratory and imaging workup as well as
      additional Docetaxel therapy every 21 days as indicated.

      An additional study clinical appointment with blood work will be organized two days post
      Desmopressin/Docetaxel treatment. Furthermore, for detailed documentation of AEs during the
      first 21 days following Desmopressin/Docetaxel therapy, subjects will be assessed weekly via
      phone, and in person by the investigator/treating medical oncologist before the second dose
      of docetaxel.
    
  